Renibus Therapeutics

Renibus Therapeutics is a private, clinical-stage biotech focused on cardiorenal and metabolic diseases with two late-stage assets. Its lead program, Veverimer, is entering a Phase 3 trial for CKD with metabolic acidosis and has received Orphan Drug Designation for anti-GBM disease. While its second Phase 3 asset, RBT-1, did not meet its primary endpoint in a cardiac surgery trial, the company is pursuing a refined development path in higher-risk patients based on post-hoc analysis. The company is led by industry veterans with a history of successful company build-outs and exits.

Develops discrete small molecule/pharmacologic agents; lead asset is a non-absorbed oral polymer that binds HCl to increase serum bicarbonate.

The metabolic acidosis in CKD space is competitive, with other companies developing novel therapies. The cardiac surgery preconditioning space is also active, with several investigational approaches. Renibus's success will depend on demonstrating superior efficacy, safety, or convenience compared to existing and pipeline competitors.